Evidence map›Paper›PMID 40205378›Full record

ArticleJournal of biological engineering2025

Termination sequence between an inducible promoter and ubiquitous chromatin opening element (UCOE) reduces gene expression leakage and silencing.

Tomoki Yanagi, Shean Fu Phen, Jonah Ayala, Deniz Ece Aydin, Susanna Jaramillo, David M Truong

Abstract read
In one paragraph

Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Programming T cells for intercellular genome editing.bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomoki YanagiDepartment of Biomedical Engineering, New York University (NYU) Tandon School of Engineering, Brooklyn, NY, USA.ORCID http://orcid.org/0000-0003-1808-2932
Shean Fu PhenDepartment of Biomedical Engineering, New York University (NYU) Tandon School of Engineering, Brooklyn, NY, USA.ORCID http://orcid.org/0009-0003-8413-710X
Jonah AyalaDepartment of Biomedical Engineering, New York University (NYU) Tandon School of Engineering, Brooklyn, NY, USA.ORCID http://orcid.org/0009-0007-8462-3908
Deniz Ece AydinDepartment of Biomedical Engineering, New York University (NYU) Tandon School of Engineering, Brooklyn, NY, USA.ORCID http://orcid.org/0000-0001-6699-793X
Susanna JaramilloDepartment of Biomedical Engineering, New York University (NYU) Tandon School of Engineering, Brooklyn, NY, USA.ORCID http://orcid.org/0009-0000-2017-0873
David M TruongDepartment of Biomedical Engineering, New York University (NYU) Tandon School of Engineering, Brooklyn, NY, USA. truond01@nyu.edu.ORCID http://orcid.org/0000-0002-5121-5111

Funding

Programmable Off-the-Shelf Dendritic Cells as an Off-the-Shelf Immunotherapy Discovery PlatformDP2AI154417 · NIAID · NEW YORK UNIVERSITY · PI TRUONG, DAVID MINH · 2021 to 2025
$2.0M
National Institute of Allergy and Infectious Diseases DP2AI154417NIAID NIH HHS DP2 AI154417
6 · The paper itself

Abstract

backgroundInducible gene expression circuits enable precise control over target gene activation and are widely used in direct reprogramming. However, their usability is often compromised by DNA methylation-induced silencing, especially in iPSCs. This deactivates genetic circuits in engineered iPSCs preventing them from being used for long-term scalable expansion of desired cell types. A2-ubiquitous chromatin opening elements (A2UCOE) have been recognized for their anti-silencing properties, but they have not been used in human iPSCs with inducible systems for direct reprogramming. This study investigates the role of A2UCOE in inducible systems and identifies strategies to eliminate associated gene leakage enabling long-term use of engineered human iPSCs.

resultsWe developed a compact all-in-one gene circuit - containing a doxycycline-inducible Tet-On system, 863 bp of A2UCOE, and FOXN1, a transcription factor critical for thymic epithelial cell (TEC) differentiation - easily deployed to new genomic sites. However, we observed significant FOXN1 gene leakage even without doxycycline, which is a novel limitation of A2UCOE. This leakage resulted in premature differentiation of iPSCs into TECs, limiting its continued use. To further investigate the relationship between A2UCOE and gene leakage, we generated A2UCOE fragments of varying lengths (1337 bp, 749 bp, and 547 bp) and found that all fragments, regardless of length, caused significant gene leakage. To solve this issue, we tested different spacer sequences between A2UCOE and the inducible promoter and found that the SV40 poly-A terminator fully eliminated FOXN1 leakage, and we show this effect is not due to AT- or GC-content. Unexpectedly, this architecture further enhanced anti-silencing effects > 60% providing prolonged stability for at least 30 days.

conclusionsThis study reveals a novel limitation of A2UCOE in inducible systems, specifically its contribution to gene leakage, which compromise sensitive systems like direct reprogramming of iPSCs. The inclusion of an SV40 poly-A sequence provides a practical solution and genomic architecture to improve the functionality of A2UCOE-based circuits. It also suggests investigating how termination of transcription modulates gene silencing as a novel design parameter. These findings have significant implications for the design of robust gene circuits, particularly in applications involving iPSCs, regenerative medicine, and cell therapy.

Indexed as

Gene SilencingGenome editingGenome engineeringSynthetic biologyTransdifferentiation

Identifiers

PMID40205378
PMCPMC11983960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.